Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

被引:20
作者
Yu, Wensheng [1 ]
Liu, Jian [1 ]
Yu, Younong [1 ]
Zhang, Vivian [1 ]
Clausen, Dane [1 ]
Kelly, Joseph [1 ]
Wolkenberg, Scott [2 ]
Beshore, Douglas [2 ]
Duffy, Joseph L. [1 ]
Chung, Christine C. [1 ]
Myers, Robert W. [1 ]
Klein, Daniel J. [2 ]
Fells, James [2 ]
Holloway, Kate [2 ]
Wu, Jin [1 ]
Wu, Guoxin [2 ]
Howell, Bonnie J. [2 ]
Barnard, Richard J. O. [2 ]
Kozlowski, Joseph [1 ]
机构
[1] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA
[2] Merck & Co Inc, 770 Sumneytown Pike, West Point, PA 19486 USA
关键词
HDAC inhibitor; HIV latency; Zinc binding group; Shock and kill; 2C4; cells; HDACs; 1; 2; 3; 6; 8; HIV latency reversing agent; HISTONE DEACETYLASE INHIBITOR; ANTIRETROVIRAL THERAPY;
D O I
10.1016/j.bmcl.2020.127197
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of ethyl ketone based HDACs 1, 2, and 3 selective inhibitors have been identified with good enzymatic and cellular activity and high selectivity over HDACs 6 and 8. These inhibitors contain a spirobicyclic group in the amide region. Compound 13 stands out as a lead due to its good potency, high selectivity, and reasonable rat and dog PK. Compounds 33 and 34 show good potency and rat PK profiles as well.
引用
收藏
页数:8
相关论文
共 20 条
[1]   Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy [J].
Archin, N. M. ;
Liberty, A. L. ;
Kashuba, A. D. ;
Choudhary, S. K. ;
Kuruc, J. D. ;
Crooks, A. M. ;
Parker, D. C. ;
Anderson, E. M. ;
Kearney, M. F. ;
Strain, M. C. ;
Richman, D. D. ;
Hudgens, M. G. ;
Bosch, R. J. ;
Coffin, J. M. ;
Eron, J. J. ;
Hazuda, D. J. ;
Margolis, D. M. .
NATURE, 2012, 487 (7408) :482-U1650
[2]   Prospects for Treatment of Latent HIV [J].
Barton, K. M. ;
Burch, B. D. ;
Soriano-Sarabia, N. ;
Margolis, D. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (01) :46-56
[3]   HIV Shock and kill [J].
Deeks, Steven G. .
NATURE, 2012, 487 (7408) :439-440
[4]   Cellular and molecular mechanisms involved in the establishment of HIV-1 latency [J].
Donahue, Daniel A. ;
Wainberg, Mark A. .
RETROVIROLOGY, 2013, 10
[5]   Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial [J].
Fidler, Sarah ;
Stohr, Wolfgang ;
Pace, Matt ;
Dorrell, Lucy ;
Lever, Andrew ;
Pett, Sarah ;
Kinloch-de Loes, Sabine ;
Fox, Julie ;
Clarke, Amanda ;
Nelson, Mark ;
Thornhill, John ;
Khan, Maryam ;
Fun, Axel ;
Bandara, Mikaila ;
Kelly, Damian ;
Kopycinski, Jakub ;
Hanke, Tomas ;
Yang, Hongbing ;
Bennett, Rachel ;
Johnson, Margaret ;
Howell, Bonnie ;
Barnard, Richard ;
Wu, Guoxin ;
Kaye, Steve ;
Wills, Mark ;
Babiker, Abdel ;
Frater, John .
LANCET, 2020, 395 (10227) :888-898
[6]   Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2 [J].
Friedman, Julia ;
Cho, Won-Kyung ;
Chu, Chung K. ;
Keedy, Kara S. ;
Archin, Nancie M. ;
Margolis, David M. ;
Karn, Jonathan .
JOURNAL OF VIROLOGY, 2011, 85 (17) :9078-9089
[7]   Histone acetylation in chromatin structure and transcription [J].
Grunstein, M .
NATURE, 1997, 389 (6649) :349-352
[8]   Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties [J].
Kinzel, Olaf ;
Llauger-Bufi, Laura ;
Pescatore, Giovanna ;
Rowley, Michael ;
Schultz-Fademrecht, Carsten ;
Monteagudo, Edith ;
Fonsi, Massimiliano ;
Paz, Odalys Gonzalez ;
Fiore, Fabrizio ;
Steinkuehler, Christian ;
Jones, Philip .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (11) :3453-3456
[9]  
Leth S, 2016, LANCET HIV, DOI DOI 10.1016/.
[10]  
Marx-Blümel L, 2017, METHODS MOL BIOL, V1510, P23, DOI 10.1007/978-1-4939-6527-4_3